China-based startup Qure Biotechnology (Shanghai) has completed a Series C1 financing round. The financing raised nearly CNY 100 million (approximately $14 million) and was led exclusively by Efung Capital. This infusion of capital will be used to accelerate QureBio's clinical trials and advance its pipeline of novel antibody therapeutics.
QureBio specialises in developing bispecific and multispecific antibody and protein therapeutics to address unmet medical needs in cancer, autoimmune diseases, and inflammatory disorders.
The company has established a suite of proprietary technology platforms – including its I2T platform and its T-cell engager and NK-cell engager platforms – which form the foundation for its pipeline of novel drug candidates. Using these platforms, QureBio has built a robust pipeline of therapeutics aimed at previously intractable diseases.
Key pipeline developments include: Q-1802 (Claudin18.2/PD-L1 bispecific antibody): Received regulatory clearance to initiate clinical trials in both China and the United States in March 2021. Phase II patient enrollment is nearly complete, and preparations are underway for Phase III clinical trials in China.
Q-1801 (SIRPα/PD-L1 bispecific antibody): Obtained clinical trial approvals in China and the US, and is poised to begin clinical studies.
PD-1 Antibody-Cytokine Fusion Candidate: An innovative fusion protein with dual functions as a PD-1 checkpoint inhibitor and a cytokine modulator, demonstrating a favorable therapeutic window. This candidate targets an area where similar approaches by larger biopharmaceutical companies have faced setbacks, and QureBio is seeking partners to accelerate its global development.
QureBio's proprietary antibody engineering technology has garnered broad industry recognition. Leveraging its platform capabilities, the company has established collaborations with leading biotechnology and pharmaceutical firms – including BRL Medicine, BioMap, Hengrui Pharma, and Precision Scientific – to co-develop novel therapies.
